Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology.

Ashish Kumar Jha, Sneha Mithun, Umeshkumar B Sherkhane, Pooj Dwivedi, Senders Puts, Biche Osong, Alberto Traverso, Nilendu Purandare, Leonard Wee, Venkatesh Rangarajan, Andre Dekker
{"title":"Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology.","authors":"Ashish Kumar Jha,&nbsp;Sneha Mithun,&nbsp;Umeshkumar B Sherkhane,&nbsp;Pooj Dwivedi,&nbsp;Senders Puts,&nbsp;Biche Osong,&nbsp;Alberto Traverso,&nbsp;Nilendu Purandare,&nbsp;Leonard Wee,&nbsp;Venkatesh Rangarajan,&nbsp;Andre Dekker","doi":"10.37349/etat.2023.00153","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer is a fatal disease and the second most cause of death worldwide. Treatment of cancer is a complex process and requires a multi-modality-based approach. Cancer detection and treatment starts with screening/diagnosis and continues till the patient is alive. Screening/diagnosis of the disease is the beginning of cancer management and continued with the staging of the disease, planning and delivery of treatment, treatment monitoring, and ongoing monitoring and follow-up. Imaging plays an important role in all stages of cancer management. Conventional oncology practice considers that all patients are similar in a disease type, whereas biomarkers subgroup the patients in a disease type which leads to the development of precision oncology. The utilization of the radiomic process has facilitated the advancement of diverse imaging biomarkers that find application in precision oncology. The role of imaging biomarkers and artificial intelligence (AI) in oncology has been investigated by many researchers in the past. The existing literature is suggestive of the increasing role of imaging biomarkers and AI in oncology. However, the stability of radiomic features has also been questioned. The radiomic community has recognized that the instability of radiomic features poses a danger to the global generalization of radiomic-based prediction models. In order to establish radiomic-based imaging biomarkers in oncology, the robustness of radiomic features needs to be established on a priority basis. This is because radiomic models developed in one institution frequently perform poorly in other institutions, most likely due to radiomic feature instability. To generalize radiomic-based prediction models in oncology, a number of initiatives, including Quantitative Imaging Network (QIN), Quantitative Imaging Biomarkers Alliance (QIBA), and Image Biomarker Standardisation Initiative (IBSI), have been launched to stabilize the radiomic features.</p>","PeriodicalId":73002,"journal":{"name":"Exploration of targeted anti-tumor therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501896/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploration of targeted anti-tumor therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37349/etat.2023.00153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 2

Abstract

Cancer is a fatal disease and the second most cause of death worldwide. Treatment of cancer is a complex process and requires a multi-modality-based approach. Cancer detection and treatment starts with screening/diagnosis and continues till the patient is alive. Screening/diagnosis of the disease is the beginning of cancer management and continued with the staging of the disease, planning and delivery of treatment, treatment monitoring, and ongoing monitoring and follow-up. Imaging plays an important role in all stages of cancer management. Conventional oncology practice considers that all patients are similar in a disease type, whereas biomarkers subgroup the patients in a disease type which leads to the development of precision oncology. The utilization of the radiomic process has facilitated the advancement of diverse imaging biomarkers that find application in precision oncology. The role of imaging biomarkers and artificial intelligence (AI) in oncology has been investigated by many researchers in the past. The existing literature is suggestive of the increasing role of imaging biomarkers and AI in oncology. However, the stability of radiomic features has also been questioned. The radiomic community has recognized that the instability of radiomic features poses a danger to the global generalization of radiomic-based prediction models. In order to establish radiomic-based imaging biomarkers in oncology, the robustness of radiomic features needs to be established on a priority basis. This is because radiomic models developed in one institution frequently perform poorly in other institutions, most likely due to radiomic feature instability. To generalize radiomic-based prediction models in oncology, a number of initiatives, including Quantitative Imaging Network (QIN), Quantitative Imaging Biomarkers Alliance (QIBA), and Image Biomarker Standardisation Initiative (IBSI), have been launched to stabilize the radiomic features.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
定量成像(放射组学)和人工智能在精确肿瘤学中的新兴作用。
癌症是一种致命疾病,是全球第二大死因。癌症的治疗是一个复杂的过程,需要基于多种模式的方法。癌症的检测和治疗从筛查/诊断开始,一直持续到病人活着。该疾病的筛查/诊断是癌症管理的开始,并随着疾病分期、计划和提供治疗、治疗监测以及持续监测和随访而继续进行。成像在癌症治疗的各个阶段都起着重要的作用。传统的肿瘤学实践认为,所有的患者在一种疾病类型上都是相似的,而生物标志物将患者划分为一种疾病类型,这导致了精确肿瘤学的发展。放射学过程的利用促进了各种成像生物标志物的进步,这些标志物在精确肿瘤学中得到了应用。成像生物标志物和人工智能(AI)在肿瘤学中的作用已经被许多研究人员研究过。现有文献提示成像生物标志物和人工智能在肿瘤学中的作用越来越大。然而,放射性特征的稳定性也受到质疑。放射组学界已经认识到,放射组学特征的不稳定性对基于放射组学的预测模型的全球推广构成了威胁。为了在肿瘤学中建立基于放射组学的成像生物标志物,需要优先建立放射组学特征的鲁棒性。这是因为在一个机构开发的放射学模型在其他机构经常表现不佳,很可能是由于放射学特征不稳定。为了在肿瘤学中推广基于放射组学的预测模型,已经启动了一系列计划,包括定量成像网络(QIN)、定量成像生物标志物联盟(QIBA)和图像生物标志物标准化计划(IBSI),以稳定放射组学特征。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
审稿时长
13 weeks
期刊最新文献
Correction: Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity? Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors Spheroids and organoids derived from colorectal cancer as tools for in vitro drug screening
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1